• Sandoz’ epoetin alfa product offering has already generated more than 400,000¹ patient years of experience worldwide

• EC approval expands Sandoz biosimilar offering to the healthcare community

Holzkirchen, 08 April, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in Binocrit’s^® (epoetin alfa) nephrology indication*.

“By expanding our …

• Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY 2015 earnings release

• No change in audited 2015 Consolidated Financial Statements for the total Group

Basel, March 31, 2016 – Novartis announced today that it has published updated 2015 quarterly and full year segment financials reflecting the new division structure, as announced in the January 27, 2016 earnings release, as if the transfers …

New research published today in a report from the IMS Institute for Healthcare Informatics – Delivering on the Potential of Biosimilar Medicines: The Role of Functioning Competitive Markets, highlights the opportunity for biosimilars to create savings of approx USD 110 billion for health systems across Europe and the U.S over the next five years. The report highlights that the extent to which biosimilars will provide these forecasted savings will depend on the policy and implementation approaches adopted by country healthcare systems.

The report, funded by Novartis, will …

• Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and low-middle-income countries

• First Novartis Access shipment delivered to Kenya where almost 30% of people die from NCDs every year

Holzkirchen, World Child Cancer Day (March 1, 2016): Sandoz is pleased to announce that the first Novartis Access shipment has just been delivered to Kenya. This shipment includes medicines against cardiovascular …

• Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)*

• Sandoz plans to complete Phase III development program and file for registration in the EU

• Deal strengthens Novartis immunology portfolio which includes investigational biosimilars adalimumab, etanercept and rituximab

Holzkirchen, 12 February, 2016 – Sandoz, a Novartis company and a global leader in biosimilars, announced today that it has acquired from Pfizer the rights for the development and commercialization of PF- …